secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001683168-23-008901
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DSMB recommends CNS Pharma's Berubicin trial continue unmodified after interim analysis
--------------------------------------------------------------------------------

- DSMB recommended continuation of Berubicin vs. Lomustine Phase 2/3 trial in recurrent GBM based on comparable overall survival.
- Enrollment expected to complete early Q1 2024; primary endpoint is overall survival.
- CEO John Climaco stated recommendation reflects acceptable efficacy and safety as defined in protocol.
- FDA has granted Fast Track and Orphan Drug Designation for Berubicin for malignant glioma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823008901/0001683168-23-008901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823008901/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-008901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer